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A B S T R A C T
The purpose of this study is to analyze the clinical experience and the effect of human
amniotic membrane transplantation on pterygium excision and bullous keratopathy.
From January 1999 to January 2001 at University Hospital »Sestre milosrdnice«
amniotic membrane transplantation was performed consecutively in 21 eyes: 11 eyes
with bullous keratopathy and 10 with recurrent pterygia. In the group with bullous
keratopathy epithelization took place in 19.6 days in 72.7% and the reduction of pain
was satisfactory. Recurrence rate in group with recurrent pterygia was 20%. Based on
the presented results it could be concluded that amniotic membrane transplantation
can be considered as an effective alternative for treating severe ocular surface diseases
and as an alternative for penetrating keratoplasty if there is a lack of grafts.
Introduction
Management of ocular surface distur-
bances still remains a therapeutically
problem despite various conservative and
surgical treatments. For some of them
previously there was no effective man-
agement and they caused a loss of vision.
The aim of this study is to evaluate
the effectiveness of application of amnio-
tic membrane in patients with bullous
keratopathy and pterygium. Pires, Prab-
hasawat and Tseng have first reported
about reconstruction of corneal surface in
symptomatic bullous keratopathy and
pterygium1,2.
Bullous keratopathy is a disease char-
acterized by corneal stromal edema with
or without epithelial bulla. Breakdown of
endothelial function leads to increased
hydration and intraepithelial edema
which could lead to recurrent or persis-
tent erosions. Patients with bullous kera-
topathy may suffer from ocular pain and
reduced vision. Bullous keratopathy cau-
sed by various intraocular surgical proce-
dures and non-surgical causes can be
treated with bandage contact lens, ante-
rior stromal punctures, epikeratoplakia,
conjunctival flap, excimer laser photo-
therapeutic karatectomy and annular
keratotomy3,4.
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Pterygium is a degenerative ocular di-
sease characterized by fibrovascular tis-
sue proliferation involving the cornea.
Because of a strong tendency to aggres-
sive recurrence after surgical therapy,
numerous methods of pterygium surgery
have been developed. The main proce-
dure involves excision of the pterygium
down to bare sclera. After excision the de-
fect can be left exposed (bare sclera exci-
sion), covered by surrounding conjunctiva
(primary closure) or covered by various
grafts (conjunctival autograft, buccal mu-
cous membrane grafts, lamellar kerato-
plasty, penetrating keratoplasty or scle-
rokeratoplasty5. An additional treatment
includes application mitomycin C or  ir-
radiation6.
Material and Methods
From January 1999 to January 2001
at the Department of Ophthalmology,
University Hospital »Sestre milosrdnice«
amniotic membrane surgery was per-
formed consecutively in 21 eyes: 11 fe-
male and 10 male. The patients were be-
tween 25 and 78 years old. An informed
consent was obtained from each patient
before the surgery. Based on the underly-
ing causes of ocular diseases they were
divided into 2 groups: 11 eyes had bullous
keratopathy and 10 recurrent pterygia.
The same surgeon performed all surgical
procedures.
Human amniotic membrane was pre-
pared and preserved as previously descri-
bed7–9. Amniotic membrane with an at-
tached placenta was obtained shortly
after Cesarean section. By serological
testing human immunodeficiency virus
(HIV), hepatitis virus type B and C and
syphilis infections have been excluded.
The placenta was cleaned by washing
with BSS containing penicillin (50  g/ml),
streptomycin (50  g/ml), neomycin (100
 g/ml), and amphotericin B (2.5  g/ml).
The amniotic membrane was separated
from the chorion and was flattened over a
nitro-cellulose filter paper with epithelial
surface up and the stromal matrix down.
Prepared amnion was placed in a plastic
container and stored at –80 °C.
All surgeries were performed with ap-
plication of laterobulbar anesthesia (2%
lidocain). In the eyes with bullous kerato-
pathy the whole epithelium was removed.
The amniotic membrane was peeled from
the nitro-cellulose filter pape. and placed
on the surface of the cornea with the epi-
thelial surface up. The amniotic mem-
brane was secured to the edge of the de-
fect by interrupted 10.0 nylon sutures.
After the transplantation, a bandage con-
tact lens was applied in 5 eyes. In the
postoperative period topical Maxitrol
(neomycin sulfate, ploymyxin B sulfate
and dexamethason) was administrated 4
times daily.
All patients with recurrent pterygium
had one or more previous surgeries. After
the pterygium body was removed, the
amniotic membrane with stromal side
down was used to cover conjunctival de-
fect. The amniotic membrane was se-
cured to the episclera with 10.0 nylon in-
terrupted perilimbal sutures and to the
cornea as well. Postoperatively, all pa-
tients were treated with topical cortico-
steroid for 4 to 6 weeks. Sutures were re-




was performed in 11 eyes with bullous
keratopathy. All patients suffered from
ocular surface pain associated with poor
visual potential (Table 1). Their average
age was 65.9 years (range 51–78 years)
and most of them had pseudophacic eyes
(N = 6) caused by extracapsular cataract
extraction (ECCE) (N = 4) and phaco-
emulsiphication (PHACO) (N = 2). On
three eyes (3/6) underwent additional oc-
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ular surgery (trabeculectomy, secondary
implantation of intraocular lens (IOL)
and vitrectomy was previously perfor-
med. In two cases of aphakic bullous ke-
ratopathy both (N = 2) were caused by
ECCE and one of them previously had
partial anterior vitrectomy and second-
ary developed glaucoma. In those with
failed corneal grafts both were pseudo-
phacic (ECCE) and one of them had had
trabeculectomy. Additional ocular dis-
eases included glaucoma in 2 eyes, non-
proliferative diabetic retinopathy in 2
eyes. All eyes had been treated with arti-
ficial teardrops, lubricants, 5 eyes with
prophylactic antibiotics and bandage con-
tact lens was applied in 5 eyes. The dura-
tion of bullous keratopathy before opera-
tion varied from 18 to 73 weeks (mean
41.3 weeks). Epithelization took place in
19.6 days (8–35 days) in 8 eyes (72.7%)
(Table 3). Amniotic membrane transplan-
tation was repeated in 3 eyes with resid-
ual pain. Amniotic membrane transplant
failed in one eye and after repeated proce-
dure the eye become pain-free. In two
eyes the pain remained in one eye the
pain was reduced and it was unchanged
in one eye. Visual acuity was improved in
1 eye from finger counting to 0.05, and in
others it remained unchanged.
In the second group amniotic mem-
brane was applied in 10 eyes with recur-
rent pterygia. Age range was 25–74 years
and the mean age was 51.2 years (Table
2). All patients have had already at least
one or more pterygium operations. In 2
eyes glaucoma was noted as pre-existing
ocular disease, and one of them had pre-
vious surgery (laser iridotomy). All eyes
had one or more previous pterygium sur-
geries (bare sclera excision and excision 
primary closure). Epithelization was
complete in 20.1 days (range 11–34 days)
(Table 3). Recurrence with fibrovascular
tissue invading the cornea occurred after
4.5 months in 2 eyes (20%). The visual
acuity was improved in 5 eyes (1–3 lines),
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TABLE 1
BULLOUS KERATOPATHY – DEMOGRAPHIC AND CLINICAL DATA BEFORE
AMNIOTIC MEMBRANE TRANSPLANTATION
Age (years) 65.9 (51–78)
Number of eyes (Male/Female) 11 (6/5)
Causes Pseudophakia (N = 6)
PHACO (N = 2)
ECCE (N = 4)
Aphakia (N = 2)
Failed graft (N = 2)
Duration (weeks) 41.3 (18–73)
Associated diagnosis
(ocular/systemic)
Glaucoma (N = 2)
Diabetes mellitus (N = 3)
Nonproliferative diabetic retinopathy (N = 2)
Previous surgery Trabeculectomy (N = 2)
Second implantation IOL (N = 1)
Vitrectomy (N = 1)
Anterior vitrectomy (N = 1)
Previous treatment Artificial tears, lubricants, prophylactic antibiotics (N = 5)
Soft contact lens (N = 4)
it remained unchanged in 4 eyes and de-
creased in 1 eye (cataract development).
Pyogenic granuloma was the postopera-
tive complication in one eye and it was
treated with excision of the granuloma
and topical corticosteroid drops.
Discussion
In this study we have evaluated the ef-
ficacy and safety of amniotic membrane
transplantation in two ocular surface dis-
orders: symptomatic bullous keratopathy
and recurrent pterygia. The amniotic
membrane transplantation has been used
since 1910. when Davis introduced it in
general surgery for skin transplanta-
tion10. In ophthalmology amniotic mem-
brane transplantation as a part of fetal
membrane transplantation was first re-
ported by De Rötth in the reconstruction
of conjunctival defects in 194011. Kim and
Tseng first reported a new dimension of
preserved and dissected amniotic mem-
brane using it for ocular surface recon-
struction in rabbits after epithelium re-
moval and limbal lamellar keratectomy7.
Amniotic membrane transplantation has
recently became very popular surgical
technique and it is used for ocular recon-
struction following chemical or thermal
burns12, advanced ocular cicatricial pem-
phigoid and Steven-Johnson syndrome13,
for pterygium excision2, conjunctival sur-
face reconstruction14,15, sterile corneal ul-
ceration9,10 and symptomatic bullous ke-
ratopathy1.
The amniotic membrane is composed
of monolayer epithelial cells, a basement
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TABLE 2
RECCURENT PTERYGIA – DEMOGRAPHIC AND CLINICAL DATA BEFORE
AMNIOTIC MEMBRANE TRANSPLANTATION
Age (years) 51.2 (25–74)
Number of eyes (Male/Female) 10 (4/6)
Duration (weeks) 27.3 (16–54)
Associated diagnosis (ocular/systemic) Glaucoma (N = 2)
Previous surgery YAG laser iridotomy (N = 1)
Previous treatment Bare sclera excision (N = 5)
Excision  primary closure (N = 6)
TABLE 3






































membrane, and an avascular stromal
matrix. The membrane permits rapid
epithelization due to various actions: it
facilitates migration of epithelial cells,
reinforces adhesion of basal epithelial
cells, promotes epithelial differentiation
and prevents epithelial apoptosis8,18. The
stromal side of the membrane also con-
tains a component that suppresses TGF-
signaling, and the proliferation and dif-
ferentiation of myofibroblast of normal
corneal and limbal fibroblasts and nor-
mal human corneal and limbal fibro-
blasts18. This action explains why amnio-
tic membrane transplantation prevents
recurrent scarring after pterygium remo-
val2. Furthermore amniotic membrane
produces basic fibroblast growth factor,
hepatocyte growth factor and transform-
ing growth factor  ; while stromal matrix
excludes inflammatory cells and contains
several forms of protease inhibitors19.
These mechanisms are the reason why
stromal inflammation is reduced after
amniotic membrane transplantation and
corneal neovascularization is mitigated.
In accordance with the previous report
from Kruse at al we have noted that ocu-
lar surface inflammation was reduced af-
ter amniotic membrane transplanta-
tion20. These finding supports recent
studies showing that the stromal matrix
of the amniotic membrane excludes in-
flammatory cells, contains various forms
of protease inhibitors, and suppresses
transforming growth factor  (TGF  ) sig-
naling and proliferation and differentia-
tion of myofibroblast of normal human
corneal and limbal fibroblasts21.
Patients with symptomatic bullous ke-
ratopathy suffer from ocular pain associ-
ated with reduced vision. As result of his-
topathological changes in cornea, poor
epithelial adhesion may persist and lead
to recurrent or persistent epithelial de-
fect. We performed amniotic membrane
transplantation in 11 eyes refractory to
conventional treatment. Eight eyes (72.7%)
became pain-free during the following pe-
riod of 19.6 days (8–35 days), which is ac-
cordance with the results of other similar
studies1,22.
Pain relief after amniotic membrane
transplantation is associated with resto-
ration of corneal epithelial integrity and
can be contributed to therapeutic amnio-
tic membrane effect whose properties
have been already mentioned.
Surgical removal of pterygium is still
a challenge. Numerous methods of surgi-
cal excision have been reported and they
all have the same goal: to achieve low re-
currence rate associated with lack of
postoperative complications. The compli-
cations in our study were minor and in-
cluded pyogenic granuloma in one eye. It
has to be stressed that in this study we
have treated only recurrent pterygia de-
fined by re-growing of the fibrovascular
tissue across the cornea.
Recurrence rate in our study was 20%
and it varies for recurrent pterygia from
9.5% to 37.5% as reported by Solomon
and Prabhasawat2. Conjunctival auto-
graft yields lower recurrence rate for re-
current pterygia varying from 0 to 25%
different reports2,23,24. This advantage
may be explained by the fact that conjun-
ctival autograft includes the limbal tissue
with stem cells that could create a limbal
barrier.
Although, conjunctival autograft achi-
eves lower recurrence rate, amniotic
membrane transplantation can be consid-
ered as the treatment of first choice in
cases in which the conjunctiva might be
needed for possible glaucoma filtering op-
erations, for large pterygia with large de-
fect that should be covered or scared bul-
bar conjunctiva.
It could be concluded that the amni-
otic membrane transplantation can be
useful in treatment of severe ocular sur-
face diseases. It may be considered as al-
ternative method for ocular surface re-
construction which is refractory to
conventional treatment.
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REKONSTRUKCIJA POVR[INE RO@NICE TRANSPLANATCIJOM
AMNIJSKE MEMBRANE
S A @ E T A K
Cilj ovog rada bio je izvijestiti o klini~kom iskustvu i rezultatima transplantacije
amnijske membrane kod operacije pterigija i bulozne keratopatije. U razdoblju od si-
je~nja 1999. do sije~nja 2001. godine, na Klinici za o~ne bolesti KB »Sestre milosrdnice«
transplantirali smo amnijsku membranu u 21 o~iju: 11 o~iju s buloznom keratopatijom
i 10 o~iju s rekurentnim pterigijem. U grupi s buloznom keratopatijom epitelizacija je
postignuta u 19,6 dana u 72,7% o~iju. Postotak recidiva u grupi s pterigijem bio je 20%.
Transplantacija amnijske membrane predstavlja djelotvorno alternativno lije~enje
te{kih bolesti prednjeg o~nog segmenta i dobra je alternativa keratoplastici u slu~aju
nedostatka transplantata.
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